Molecular subtypes of metastatic urothelial carcinoma and treatment options
Urothelial carcinoma is a common cancer and patients with metastatic urothelial cancer (mUC) have very poor outcomes. Many mUC patients do not have durable responses to systemic treatment and are exposed to toxic side effects that negatively impact the patient’s quality of life. Identifying novel biomarkers for therapy and selecting the best treatment option for […]
